Fabtech Technologies IPO is a book-built issue worth ₹230.35 crore. The issue is entirely a fresh issue of 1.21 crore shares, raising the whole issue amount. The IPO will open for subscription on September 29, 2025, and close on October 01, 2025.
The basis of allotment is expected to be finalised on October 03, 2025, with tentative listing scheduled on BSE and NSE for October 07, 2025. The price band for the Fabtech Technologies IPO has been fixed between ₹181 to ₹191 per share.
Investors can bid for Fabtech Technologies IPO with a minimum of 1 lot of 75 shares. For retail investors, the minimum investment required is ₹14,325. For small non-institutional investors (sNII), the lot size stands at 14 lots, equal to 1,050 shares, amounting to ₹2,00,550. For big non-institutional investors (bNII), the lot size is 70 lots, which translates to 5,250 shares, requiring an investment of ₹10,02,750.
Unistone Capital Pvt Ltd is the book running lead manager (BRLM) and Bigshare Services Pvt Ltd is the registrar of the issue. Detailed information is available in the Fabtech Technologies IPO RHP.
Fabtech Technologies IPO Objectives
The company will deploy the funds from the public issue towards following:
- Financing working capital requirements
- For inorganic growth initiatives through acquisitions. 
- General corporate purposes.
About Fabtech Technologies Limited
incorporated in 2018, Fabtech Technologies Limited is a global enterprise headquartered in India, specialising in turnkey engineering solutions for the pharmaceutical, biotechnology, and healthcare sectors. With a presence in over 62 countries across the Middle East, Africa, Asia, Europe, Latin America, and North America, the organization has established a strong footprint in several key emerging markets, including Bangladesh, Egypt, Ethiopia, India, Kenya, the Kingdom of Saudi Arabia, Morocco, Nicaragua, Nigeria, South Africa, Turkey, the UAE, the USA, and Tanzania (Source: CRISIL Report).
The company offers end-to-end engineering expertise and infrastructure to deliver fully integrated solutions for aseptic manufacturing facilities, covering the entire project lifecycle—from concept and design to execution and certification.
Its turnkey services for greenfield projects encompass all critical stages such as disease identification, project planning, facility design, engineering, procurement, quality assurance, logistics management, and final installation and commissioning. These services are tailored for a diverse clientele across various geographies, with a special focus on emerging economies.
In addition to complete turnkey solutions, the Company also provides modular engineering services, including equipment procurement, supply, and logistics management, which may be offered independently or as part of larger greenfield or brownfield initiatives.
Industry Outlook
- The Indian pharmaceutical industry is the world’s third-largestby volume, valued at approximately Rs 4.5 trillion as of fiscal 2025, encompassing both bulk drugs and formulation exports.
- The Indian domestic formulation market has experienced robust growth, contributing around 2% of the global pharmaceutical market and growing at a CAGR of 9% from FY2020 to FY2025.
- Pharmaceutical companies’ capex activities are primarily categorized into regulatory capex—driven by compliance requirements such as approvals and licenses—and strategic capex aimed at expansion and innovation.
- Turnkey pharmaceutical engineering solution providers play a vital role throughout the capex value chain, starting with consulting and advisory services that include comprehensive market research and analysis to identify project-specific needs and objectives.
How To Apply for the Fabtech Technologies IPO Online?
- Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
- Locate the IPO Section: Navigate to the 'IPO' section on the platform.
- Select IPO: Find and select the Fabtech Technologies IPO from the list of open IPOs.
- Enter the Lot Size: Specify the number of lots you want to bid for.
- Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
- Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.
How To Check the Allotment Status of Fabtech Technologies IPO?
Steps to check IPO allotment status on Angel One’s app:
- Log in to the Angel One app.
- Go to the IPO Section and then to IPO Orders.
- Select the individual IPO that you had applied for and check the allotment status.
- Angel One will notify you of your IPO allotment status via push notification and email.
Contact Details of Fabtech Technologies IPO
715, Janki Centre, Off. Veera Desai Road, Andheri West, Mumbai - 400 053, Maharashtra, India.
Phone: +91 226 554 0300
E-mail: cs@fabtechnologies.com
Fabtech Technologies IPO Reservation
|
Investor Category |
Shares |
|
QIB (Qualified Institutional Buyers) |
Not more than 50% of the Net Issue |
|
Retail Individual Investors (RII) |
Not less than 35% of the Net Issue |
|
NII (Non-Institutional Investors) |
Not less than 15% of the Net Issue |
Fabtech Technologies IPO Lot Size Details
|
Application |
Lots |
Shares |
Amount |
|
Retail (Min) |
1 |
75 |
₹14,325 |
|
Retail (Max) |
13 |
975  |
₹1,86,225 |
|
S-HNI (Min) |
14 |
1,050  |
₹2,00,550 |
|
S-HNI (Max) |
69 |
5,175 |
₹9,88,425 |
|
B-HNI (Min) |
70 |
5,250 |
₹10,02,750 |
Fabtech Technologies IPO Promoter Holding
Aasif Ahsan Khan, Hemant Mohan Anavkar, Aarif Ahsan Khan and Manisha Hemant Anavkar are the promoters of the company.
|
Share Holding Pre-Issue |
94.61% |
|
Share Holding Post Issue  |
- |
Note: Equity dilution will be determined by subtracting the Shareholding Post Issue from the Shareholding Pre Issue.
Key Performance Indicators for Fabtech Technologies IPO
|
KPI |
Value |
|
ROE (%) |
30.46 |
|
ROCE (%) |
24.46 |
|
RoNW (%) |
26.83 |
|
EBITDA Margin (%) |
14.07 |
|
PAT Margin (%) |
13.83 |
Fabtech Technologies IPO Prospectus
Fabtech Technologies IPO Registrar and Lead Managers
Fabtech Technologies IPO Lead Managers
- Unistone Capital Pvt Ltd
Registrar for Fabtech Technologies IPO
Bigshare Services Pvt Ltd
- Contact Number: +91 22 6263 8200
Email Address: ipo@bigshareonline.com
Financial Performance of Fabtech Technologies Limited
| Particulars | Year ending on March 31, 2025 | Year ending on March 31, 2024 |
|---|---|---|
| Revenue from Operations (in ₹ lakhs) | 32,666.85 | 22,613.63 |
| Profit/loss After Tax (in ₹ lakhs) | 4,645.30 | 2,721.74 |
| PAT Margin (%) | 13.83 | 11.80 |
| EBITDA (in ₹ lakhs) | 4,727.91 | 3,975.11 |
| EBITDA Margin (%) | 14.07 | 17.24 |
| Net Worth (in ₹ lakhs) | 17,311.39 | 13,188.22 |
| Return on Equity (%) | 30.46 | 24.65 |
Know before investing
Strengths
8Fabtech Technologies operates in 57 countries, having served 289 international clients, demonstrating strong global reach and market credibility.
Recognised as a leading turnkey engineering solutions provider, offering end-to-end services from design to commissioning in the pharmaceutical sector.
Operates on a capital-efficient model, leveraging third-party and related-entity procurement to reduce costs and improve scalability.
Equipped with proprietary software tools and experienced leadership, enabling faster project execution and optimized resource deployment.
A steadily expanding order book reflects diversification across geographies and sectors, with consistent growth from FY2023 to FY2025.
Seeks to increase engagements with government clients in Africa, capitalizing on emerging healthcare infrastructure investments.
Plans to drive growth through acquisitions in India, UAE, Saudi Arabia, and Egypt, to strengthen its integrated supply chain and reduce costs.
Aims to expand its customer portfolio beyond pharmaceuticals, into adjacent sectors like biotech and healthcare infrastructure.
Risks
8The Company’s actual orders received have been less than 11% of total proposals, risking adverse impacts if lead generation and conversion remain low.
A relatively short operating history may hinder the Company’s ability to compete effectively and make future performance difficult to predict.
Future projects and current order book entries may face delays, modifications, or cancellations, potentially affecting financial stability and reputation.
Heavy reliance on Associate and Promoter Group companies for equipment procurement could impact project execution if supply issues arise.
A significant portion of revenue depends on a limited number of projects, making the Company vulnerable to financial impacts from project cancellations.
Unforeseen project delays or cancellations beyond the Company’s control may adversely affect profitability and operational results.
Limited market presence compared to established players may challenge the Company’s ability to secure future contracts.
Operating in multiple emerging and complex markets exposes the Company to regulatory, logistical, and geopolitical risks.
